RxDoctor Payments Data

Ashwin Thiagarajasubramanian, MD

Cardiovascular Disease · Phoenixville, PANPI 1134562879

Payments from drug & device makers

$2,247in general payments, 2019–2025

Across 27 payments — averaging $83.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AstraZeneca$401
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$281
  • Lantheus Medical Imaging, Inc.$151
  • E.r. Squibb & Sons, L.L.C.$128
  • Medtronic$72
  • plus $197 from 5 others

What the payments were for

  • Travel & lodging$97243%
  • Food & beverage$1,27557%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,247 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,356
Medicare patients
344
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$225,760
XareltoRivaroxaban141$153,027
EntrestoSacubitril/Valsartan77$90,017
FarxigaDapagliflozin Propanediol14$22,023
JardianceEmpagliflozin24$14,612
Repatha SureclickEvolocumab12$6,463
Metoprolol Succinate314$5,792
Dofetilide13$4,724
Bumetanide54$3,087
Rosuvastatin Calcium186$2,632
Amiodarone Hcl62$2,575
Metoprolol Tartrate313$2,261
Flecainide Acetate51$2,129
Atorvastatin Calcium189$2,101
Spironolactone203$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$62$90,01777 claims
AstraZenecaFarxiga$401$22,02314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Phoenixville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →